

e-Therapeutics plc

("e-Therapeutics" or "the Company")

Director's Award of Options

e-Therapeutics (AIM: ETX), the drug discovery and development company, announces that on 12 August 2011 Dr Daniel Elger, the Company's CFO, was awarded options to acquire at par value 400,000 new ordinary shares of 0.1p each in the Company under the terms of the Company's LTIP scheme, with conditions as below:

- the options may only be exercised within a six-month period following the third anniversary of their grant and provided that the Company's share price at that third anniversary is not less than 100 pence;

- the options may be exercised sooner in the event of a change of control, but only if the price offered by the party acquiring control of the Company is at least 67 pence per share;

Following this option award and Dr Elger's recent purchase of shares, he now has the following interests in ordinary shares of the Company:

- 15,000 ordinary shares (representing 0.01% of the issued share capital of the Company)

- options over a total of 400,000 shares, as detailed above

As at the date of this announcement, and including the above, there are options and warrants outstanding over 4,541,701 ordinary shares in the Company, amounting to approximately 3.3% of the current issued share capital.

Contacts

e-Therapeutics plc Tel: +44 (0) 191 233 1317

Malcolm Young

Panmure Gordon (UK) Limited Tel: +44 (0)20 7459 3600

Aubrey Powell / Andrew Burnett